David Sobek

Sobek writes on biotech, with a focus on small-cap oncology and antibiotics companies. He received a PhD in political science from Penn State in 2003. He is the proprietor of Sobek Analytics.


Recent Articles By The Author

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

Gilead Buying Vertex Among Bold Biotech Stock Predictions for 2015

The 2015 biotech stock predictions of TheStreet contributor David Sobek.

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses

Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

Foundation Medicine Winning Increased Insurance Coverage for Genetic Cancer Tests

Coverage decisions are still likely to slowly build over time but it is a clear positive that we are seeing the early adopters start to reimburse for Foundation's cancer tests.

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

Strong Prostate Cancer Drug Sales Will Help Medivation Expand Pipeline

The diversification away from Xtandi has only just begun.

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

Stock Weakness in Seattle Genetics, Gilead Sciences Belies Fundamental Strengths

Some perspective on recent positive news, which nonetheless, caused Seattle Genetics and Gilead shares to fall.